GLENMARK PHARMA Fact Sheet, GLENMARK PHARMA Financial Results - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

GLENMARK PHARMA Fact Sheet    (GLPH)


Find Out: The Hidden Opportunity in EV Stocks


Here is the latest financial fact sheet of GLENMARK PHARMA. For more details, see the GLENMARK PHARMA quarterly results and GLENMARK PHARMA share price and chart. For a sector overview, read our pharmaceuticals sector report.

GLENMARK PHARMA Price History

Price Rs 487.6
Mkt Cap Rs m 137,585
Vol '000 58.0
P/E X 12.9
P/CF X 9.7
EPS (TTM) Rs 37.7
1 Day % 2.4
No. of shares m 282.17
1 Week % -2.0
1 Month % -4.3
1 Year % 0.4
52 week H/L Rs 690.6/442.2
As on Jan 28, 2022 (Close)
* Results Consolidated
Excel EXPORT | DO YOU LIKE THESE FACTSHEETS? TELL US!

GLENMARK PHARMA Financials

No. of Mths
Year Ending
12
Mar-17
*
12
Mar-18
*
12
Mar-19
*
12
Mar-20
*
12
Mar-21
*
5-Yr Chart
Click to enlarge
GLENMARK PHARMA EQUITY SHARE DATA
High Rs993930712660573 
Low Rs729517484168195 
Sales per share (Unadj.) Rs318.0320.6349.6377.1387.8 
Earnings per share (Unadj.) Rs39.328.532.827.534.4 
Diluted earnings per shareRs39.328.532.827.534.4 
Cash flow per share (Unadj.) Rs48.739.244.342.350.1 
Dividends per share (Unadj.) Rs2.002.002.002.502.50 
Adj. dividends per shareRs2.002.002.002.502.50 
Avg Dividend yield %0.20.30.30.60.7 
Book value per share (Unadj.) Rs159.2182.6198.3214.7249.6 
Adj. book value per shareRs159.2182.6198.3214.7249.6 
Shares outstanding (eoy) m282.17282.17282.17282.17282.17 
Bonus / Rights / Conversions  ----- 
Price / Sales ratio x2.72.31.71.11.0 
Avg P/E ratio x21.925.418.215.011.2 
P/CF ratio (eoy) x17.718.513.59.87.7 
Price / Book Value ratio x5.44.03.01.91.5 
Dividend payout %5.17.06.19.17.3 
Avg Mkt Cap Rs m242,989204,205168,617116,775108,353 
No. of employees `000NANANANANA 
Total wages/salary Rs m16,40818,71820,56122,54823,437 
Avg. sales/employee Rs ThNMNMNMNMNM 
Avg. wages/employee Rs ThNMNMNMNMNM 
Avg. net profit/employee Rs ThNMNMNMNMNM 
GLENMARK PHARMA INCOME DATA
Net Sales Rs m89,73190,45898,655106,410109,439 
Other income Rs m3749142,0811,596502 
Total revenues Rs m90,10591,372100,736108,006109,941 
Gross profit Rs m19,55816,15417,53017,31021,289 
Depreciation Rs m2,6443,0193,2594,1724,436 
Interest Rs m2,3732,8563,3463,7733,531 
Profit before tax Rs m14,91411,19313,00610,96113,825 
Minority Interest Rs m00000 
Prior Period Items Rs m00000 
Extraordinary Inc (Exp) Rs m00000 
Tax Rs m3,8273,1553,7563,2014,124 
Profit after tax Rs m11,0888,0399,2507,7609,701 
Gross profit margin %21.817.917.816.319.5 
Effective tax rate %25.728.228.929.229.8 
Net profit margin %12.48.99.47.38.9 
GLENMARK PHARMA BALANCE SHEET DATA
Current assets Rs m68,74669,88766,96868,03673,596 
Current liabilities Rs m27,02732,87940,21141,26042,010 
Net working cap to sales %46.540.927.125.228.9 
Current ratio x2.52.11.71.61.8 
Inventory Days Days55567 
Debtors Days Days9894818386 
Net fixed assets Rs m35,78042,86452,09064,25567,093 
Share capital Rs m282282282282282 
"Free" reserves Rs m44,62951,24855,66460,28670,148 
Net worth Rs m44,91151,53055,94660,56870,430 
Long term debt Rs m45,36341,41835,73840,43038,888 
Total assets Rs m104,526112,751119,058132,291140,689 
Interest coverage x7.34.94.93.94.9 
Debt to equity ratio x1.00.80.60.70.6 
Sales to assets ratio x0.90.80.80.80.8 
Return on assets %12.99.710.68.79.4 
Return on equity %24.715.616.512.813.8 
Return on capital %19.115.117.814.615.9 
Exports to sales %00000 
Imports to sales %00000 
Exports (fob) Rs m00000 
Imports (cif) Rs m00000 
Fx inflow Rs m56,15236,31762,99847,73735,753 
Fx outflow Rs m8,0849,72022,85918,88112,023 
Net fx Rs m48,06726,59840,14028,85623,729 
GLENMARK PHARMA CASH FLOW
From Operations Rs m 6,574 16,481 13,242 13,924 11,312 
From Investments Rs m -7,123 -10,133 -6,990 -7,835 -6,752 
From Financial Activity Rs m 5,432 -4,685 -7,387 -4,447 -4,418 
Net Cashflow Rs m 1,992 1,770 -2,971 1,740 278 
* Results Consolidated
Source: Accord Fintech, Equitymaster

Share Holding

Promoters 46.7%
Institution 35.0%
Non-Institution 18.3%
Total 100.0%
Free Float 53.4%
Pledged promoter holdings 0.0%
Shareholding as on Dec 2021
 

Company Information

Regd Off B/2 Mahalaxmi Chambers, 22 Bhulabhai Desai Road, Mumbai - 400026
E-mail webmaster@glenmarkpharma.com Web www.glenmarkpharma.com
Tel Fax
Sector PHARMACEUTICALS Group Glenmark
Tr Agent K FIN Technologies Pvt Ltd.-(Karvy Fintech Pvt Ltd.), Karvy Selenium Tower B Plot 31-32, Gachibowli Financial District, Nanakramguda
Auditor Walker, Chandiok & Co.
CHM: Glenn Saldanha (MD) COMP SEC: Sanjay Kumar Chowdhary YEAR OF INC: 1977 BSE CODE: 532296 FV (Rs): 1 DIV YIELD (%): 0.5

Read: GLENMARK PHARMA 2020-21 Annual Report Analysis

More Pharmaceuticals Company Fact Sheets:   SUN PHARMA    LUPIN    CIPLA    AUROBINDO PHARMA    DR. REDDYS LAB    

Compare GLENMARK PHARMA With:   SUN PHARMA    LUPIN    CIPLA    AUROBINDO PHARMA    DR. REDDYS LAB    




Today's Market

Indian Indices End Flat Amid High Volatility; Maruti Suzuki & Tech Mahindra Among Top Losers(Closing)

Indian share markets witnessed volatile trading activity throughout the day today and ended marginally lower.

Views on news

GLENMARK PHARMA 2020-21 Annual Report Analysis (Annual Result Update)

Sep 6, 2021 | Updated on Sep 6, 2021

Here's an analysis of the annual report of GLENMARK PHARMA for 2020-21. It includes a full income statement, balance sheet and cash flow analysis of GLENMARK PHARMA. Also includes updates on the valuation of GLENMARK PHARMA.

GLENMARK PHARMA Announces Quarterly Results (1QFY22); Net Profit Up 20.7% (Quarterly Result Update)

Aug 16, 2021 | Updated on Aug 16, 2021

For the quarter ended June 2021, GLENMARK PHARMA has posted a net profit of Rs 3 bn (up 20.7% YoY). Sales on the other hand came in at Rs 30 bn (up 26.4% YoY). Read on for a complete analysis of GLENMARK PHARMA's quarterly results.

Sun Pharma vs Dr Reddy's: Which is Better? (Views On News)

Dec 16, 2021

In an extremely competitive market, two pharma companies are competing against each other to grab the top spot.

5 Stocks to Watch Out for Amid the Omicron Outbreak (Views On News)

Dec 3, 2021

As the new variant of Covid-19 emerges, keep an eye on these stocks.

This Stock Just Made a Historical Debut on the Exchanges (Views On News)

Nov 15, 2021

Shares of the company listed at premium of 253% from its IPO price, the highest ever.

More Views on News

Most Popular

These 5 Penny Stocks are Held by Rakesh Jhunjhunwala. Worth a Look? (Views On News)

Jan 18, 2022

Rakesh Jhunjhunwala is holding these penny stocks in his portfolio for several years now.

Tech Mahindra's CTC Acquisition: Too Expensive? (Views On News)

Jan 18, 2022

Tech Mahindra's acquisition of European IT-company fails to excite investors.

5 Hidden Tata Group Companies to Add to Your Watchlist (Views On News)

Jan 18, 2022

Here's all you need to know about these five Tata group stocks that aren't as popular as the others.

4 'Digital India' Stocks to Add to Your 2022 Watchlist (Views On News)

Jan 28, 2022

Digitisation is touching every aspect of our lives. As this megatrend picks up pace, there will be companies benefitting from it for years to come.

Insiders are Buying into these 6 Stocks Aggressively. More Details here... (Views On News)

Jan 19, 2022

While promoter holding is an important parameter, it should not be the sole reason for buying a stock.

More

Become A Smarter Investor
In Just 5 Minutes

Multibagger Stock Guide 2022
Get our special report Multibagger Stocks Guide (2022 Edition) Now!
We will never sell or rent your email id.
Please read our Terms

TRACK GLENMARK PHARMA

  • Track your investment in GLENMARK PHARMA with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

MORE ON GLENMARK PHARMA

GLENMARK PHARMA - SYNCOM HEALTHCARE COMPARISON

COMPARE GLENMARK PHARMA WITH

MARKET STATS